Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
CGEM
Valuation N/A
Cullinan Therapeutics, Inc.
Price$20.59
Model IV—
P/IV—
Market implies +58.0%/yr
vs model +15.0% · above model
CGEN
Deeply undervalued
COMPUGEN LTD
Price$2.47
Model IV$8.67
P/IV0.30
Discount 72%
Return to IV: +251.0%
Market implies -1.7%/yr
vs model +25.0% · below model
CGNX
Deeply overvalued
COGNEX CORP
Price$64.22
Model IV$14.01
P/IV4.70
Premium +358%
Return to IV: -78.2%
Owner yield 1.4%
10-yr IRR -7.9% · steady
Market implies +25.5%/yr
vs model +4.5% · above model
CGON
Valuation N/A
CG Oncology, Inc.
Price$72.35
Model IV—
P/IV—
Market implies +78.2%/yr
vs model +50.0% · above model
CGTX
Valuation N/A
COGNITION THERAPEUTICS INC
Price$0.98
Model IV—
P/IV—
CHE
Deeply undervalued
CHEMED CORP
Price$515.97
Model IV$1,257.76
P/IV0.34
Discount 59%
Return to IV: +143.8%
Owner yield 4.3%
10-yr IRR 12.9% · grower
Market implies +3.1%/yr
vs model +18.7% · below model
CHRS
Valuation N/A
Coherus Oncology, Inc.
Price$1.33
Model IV—
P/IV—
Market implies +57.0%/yr
vs model +2.0% · above model
CING
Valuation N/A
Cingulate Inc.
Price$5.17
Model IV—
P/IV—
CINGW
Valuation N/A
Cingulate Inc.
Price$0.01
Model IV—
P/IV—
CLDI
Valuation N/A
Calidi Biotherapeutics, Inc.
Price$1.17
Model IV—
P/IV—
CLDX
Valuation N/A
Celldex Therapeutics, Inc.
Price$39.18
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CLGN
Valuation N/A
CollPlant Biotechnologies Ltd
Price$3.40
Model IV—
P/IV—
Market implies +60.5%/yr
vs model +2.0% · above model
CLIR
Fairly valued
ClearSign Technologies Corp
Price$3.85
Model IV$3.84
P/IV1.21
Premium +0%
Return to IV: -0.3%
Market implies -2.6%/yr
vs model +50.0% · below model
CLLS
Valuation N/A
Cellectis S.A.
Price$3.10
Model IV—
P/IV—
CLNN
Valuation N/A
Clene Inc.
Price$3.57
Model IV—
P/IV—
Market implies +100.5%/yr
vs model +2.0% · above model
CLPT
Valuation N/A
ClearPoint Neuro, Inc.
Price$13.72
Model IV—
P/IV—
Market implies +45.5%/yr
vs model +22.7% · above model
CLRB
Valuation N/A
Cellectar Biosciences, Inc.
Price$2.31
Model IV—
P/IV—
CLYM
Valuation N/A
Climb Bio, Inc.
Price$14.25
Model IV—
P/IV—
CMMB
Valuation N/A
Chemomab Therapeutics Ltd.
Price$2.58
Model IV—
P/IV—
CMND
Valuation N/A
Clearmind Medicine Inc.
Price$0.97
Model IV—
P/IV—
CMPS
Valuation N/A
COMPASS Pathways plc
Price$14.54
Model IV—
P/IV—
CMPX
Valuation N/A
Compass Therapeutics, Inc.
Price$2.00
Model IV—
P/IV—
Market implies +82.9%/yr
vs model +15.0% · above model
CNMD
Undervalued
CONMED Corp
Price$46.95
Model IV$65.94
P/IV0.54
Discount 29%
Return to IV: +40.4%
Owner yield 9.4%
10-yr IRR 20.5% · moderate
Market implies +2.2%/yr
vs model +9.4% · below model
CNSP
Valuation N/A
CNS Pharmaceuticals, Inc.
Price$5.84
Model IV—
P/IV—
CNTA
Valuation N/A
Centessa Pharmaceuticals plc
Price$40.50
Model IV—
P/IV—
Market implies +83.7%/yr
vs model +15.0% · above model
CNTB
Valuation N/A
Connect Biopharma Holdings Ltd
Price$2.04
Model IV—
P/IV—
Market implies +63.9%/yr
vs model +15.0% · above model
CNTN
Valuation N/A
Canton Strategic Holdings, Inc.
Price$2.11
Model IV—
P/IV—
CNTX
Valuation N/A
Context Therapeutics Inc.
Price$0.35
Model IV—
P/IV—
CNXU
Valuation N/A
Conexeu Sciences Inc.
Price$4.46
Model IV—
P/IV—
COAG
Valuation N/A
Hemab Therapeutics Holdings, Inc.
Price$39.40
Model IV—
P/IV—
COCH
Valuation N/A
Envoy Medical, Inc.
Price$0.74
Model IV—
P/IV—
Market implies +46.9%/yr
vs model +15.0% · above model
COCHW
Valuation N/A
Envoy Medical, Inc.
Price$0.05
Model IV—
P/IV—
Market implies +25.0%/yr
vs model +15.0% · above model
COCP
Valuation N/A
Cocrystal Pharma, Inc.
Price$1.24
Model IV—
P/IV—
CODX
Valuation N/A
Co-Diagnostics, Inc.
Price$1.12
Model IV—
P/IV—
Market implies +36.5%/yr
vs model +2.0% · above model
COGT
Valuation N/A
Cogent Biosciences, Inc.
Price$33.41
Model IV—
P/IV—
COHR
Valuation N/A
COHERENT CORP.
Price$317.36
Model IV—
P/IV—
Market implies +32.7%/yr
vs model +17.0% · above model
COHU
Valuation N/A
COHU INC
Price$57.08
Model IV—
P/IV—
Market implies +36.6%/yr
vs model +2.0% · above model
COLL
Deeply undervalued
COLLEGIUM PHARMACEUTICAL, INC
Price$22.75
Model IV$372.51
P/IV0.09
Discount 94%
Return to IV: +1,537.4%
Owner yield 29.7%
10-yr IRR 53.4% · grower
Market implies -19.5%/yr
vs model +24.5% · below model
CON
Deeply undervalued
Concentra Group Holdings Parent, Inc.
Price$34.95
Model IV$37.81
P/IV0.66
Discount 8%
Return to IV: +8.2%
Owner yield 4.3%
10-yr IRR 7.9% · moderate
Market implies +5.8%/yr
vs model +8.5% · in line
COO
Overvalued
COOPER COMPANIES, INC.
Price$55.29
Model IV$44.25
P/IV1.38
Premium +25%
Return to IV: -20.0%
Owner yield 2.8%
10-yr IRR 3.0% · moderate
Market implies +10.5%/yr
vs model +9.2% · in line
CORT
Valuation N/A
CORCEPT THERAPEUTICS INC
Price$112.79
Model IV—
P/IV—
Market implies +32.2%/yr
vs model +20.1% · above model
COYA
Valuation N/A
Coya Therapeutics, Inc.
Price$4.38
Model IV—
P/IV—
Market implies +21.5%/yr
vs model +15.0% · above model
CPHI
Valuation N/A
CHINA PHARMA HOLDINGS, INC.
Price$0.76
Model IV—
P/IV—
Market implies -2.7%/yr
vs model +2.0% · below model
CPIX
Overvalued
CUMBERLAND PHARMACEUTICALS INC
Price$6.39
Model IV$5.02
P/IV1.22
Premium +27%
Return to IV: -21.4%
Owner yield 3.5%
10-yr IRR 4.4% · moderate
Market implies +7.0%/yr
vs model +7.3% · in line
CPRX
Deeply undervalued
CATALYST PHARMACEUTICALS, INC.
Price$31.49
Model IV$82.62
P/IV0.38
Discount 62%
Return to IV: +162.4%
Owner yield 4.9%
10-yr IRR 14.7% · grower
Market implies +6.0%/yr
vs model +25.0% · below model
CRBP
Valuation N/A
Corbus Pharmaceuticals Holdings, Inc.
Price$6.92
Model IV—
P/IV—
Market implies +58.1%/yr
vs model +15.0% · above model
CRBU
Valuation N/A
Caribou Biosciences, Inc.
Price$1.27
Model IV—
P/IV—
Market implies +64.6%/yr
vs model +3.8% · above model
CRDF
Valuation N/A
Cardiff Oncology, Inc.
Price$1.21
Model IV—
P/IV—
Market implies +77.6%/yr
vs model +13.4% · above model
CRDL
Valuation N/A
Cardiol Therapeutics Inc.
Price$2.00
Model IV—
P/IV—
CRIS
Valuation N/A
CURIS INC
Price$1.13
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +2.0% · above model
CRMD
Valuation N/A
CorMedix Inc.
Price$7.83
Model IV—
P/IV—
CRNX
Valuation N/A
Crinetics Pharmaceuticals, Inc.
Price$84.95
Model IV—
P/IV—
Market implies +71.6%/yr
vs model +50.0% · above model
CRON
Overvalued
Cronos Group Inc.
Price$3.14
Model IV$2.46
P/IV1.15
Premium +27%
Return to IV: -21.5%
Market implies -6.6%/yr
vs model +22.8% · below model
CRSP
Valuation N/A
CRISPR Therapeutics AG
Price$51.72
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +2.0% · above model
CRVO
Valuation N/A
CervoMed Inc.
Price$2.57
Model IV—
P/IV—
Market implies +22.6%/yr
vs model +15.0% · above model
CRVS
Valuation N/A
Corvus Pharmaceuticals, Inc.
Price$12.91
Model IV—
P/IV—
CSBR
Deeply undervalued
CHAMPIONS ONCOLOGY, INC.
Price$5.10
Model IV$11.38
P/IV0.51
Discount 55%
Return to IV: +123.2%
Owner yield 0.5%
10-yr IRR -14.6% · moderate
Market implies -4.6%/yr
vs model +9.5% · below model
CSTL
Deeply undervalued
CASTLE BIOSCIENCES INC
Price$32.33
Model IV$70.42
P/IV0.07
Discount 54%
Return to IV: +117.8%
Market implies -17.0%/yr
vs model +38.3% · below model
CTKB
Deeply overvalued
Cytek Biosciences, Inc.
Price$4.61
Model IV$1.73
P/IV2.42
Premium +167%
Return to IV: -62.5%
Market implies +12.5%/yr
vs model +12.0% · in line
CTMX
Valuation N/A
CytomX Therapeutics, Inc.
Price$3.29
Model IV—
P/IV—
Market implies +21.4%/yr
vs model +19.5% · in line